checkAd

     569  0 Kommentare A2 Acquisition Corp. Announces TSXV Conditional Approval and the Increase of Medicenna Therapeutics Inc. Offering Size to $4,000,000 - Seite 2

    Further Information

    All information contained in this news release with respect to A2 and Medicenna was supplied by the parties respectively, for inclusion herein, and each party and its directors and officers have relied on the other party for any information concerning the other party.

    Completion of the Proposed Transaction is subject to a number of conditions, including but not limited to, final Exchange acceptance. There can be no assurance that the Proposed Transaction will be completed as proposed or at all.

    Investors are cautioned that, except as disclosed in the Filing Statement, any information released or received with respect to the transaction may not be accurate or complete and should not be relied upon. Trading in the securities of a capital pool company should be considered highly speculative.

    The Exchange has in no way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release.

    Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Exchange) accepts responsibility for the adequacy or accuracy of this press release.

    This news release contains forward-looking statements relating to the timing and completion of the Proposed Transaction, the future operations of the Company and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release, including, without limitation, statements regarding the Proposed Transaction and the future plans and objectives of the Company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include the failure to satisfy the conditions to completion of the Proposed Transaction set forth above and other risks detailed from time to time in the filings made by the Company with securities regulations.

    Seite 2 von 3



    Verfasst von Marketwired
    A2 Acquisition Corp. Announces TSXV Conditional Approval and the Increase of Medicenna Therapeutics Inc. Offering Size to $4,000,000 - Seite 2 CALGARY, ALBERTA--(Marketwired - Feb. 27, 2017) - NOT FOR DISSEMINATION IN THE U.S. OR THROUGH U.S. NEWSWIRES A2 Acquisition Corp. ("A2" or the "Company") (TSX VENTURE:APD.P), a capital pool company, is pleased to announce that the …